News Releases

News Releases

Letter From the CEO: COVID-19 Update

RESEARCH TRIANGLE PARK, NC– March 23, 2020

All -

At Synteract, everything we do, is because patients are waiting. With that mission in mind, I want to take a moment to touch base and give you a current state of our active response plan. First and foremost, the health and well-being of all employees, their families, patients, clients, and partners is our priority. This pandemic has brought out the best in our collective teams at all levels, and I continue to be in awe of the decisions and actions that this great group of people are able to achieve during times of adversity.

Staying the Regulatory Course

We are staying current with health authority guidances, including Centers for Disease Control and Prevention (CDC & ECDC), World Health Organization (WHO), as well as governments in all geographic locations where we live, work, and operate. Recently received updates from the FDA, EMA and MHRA continue to provide guidance on how to maintain the effectiveness of trials currently underway and trials beginning. This together with our own project planning and risk mitigation processes has provided an excellent framework to support our partners in making educated decisions.

Such fluidity on a global scale is impacting how we conduct clinical trials. To help mitigate risk, we are proactively working across our teams to assess the potential impact of COVID-19 on overall trial conduct. The collaborative actions taken in partnership with our customers has been a significant point of success in maintaining trial integrity and patient safety above all else.

Work Continuity

Our Operations Team has been working with many of your teams to develop continuity plans for your projects while assessing the ever-changing environment and impact to patients, sites, and required deliverables. Our teams are positioned to assist in the development of alternative delivery plans such as remote monitoring visits versus on-site monitoring visits. Our Biometrics teams continue to manage the data from trials effectively and are now managing the requirements for the continuance and analysis of trials going forward.

In the meantime, to protect the health and safety of our teams, while maintaining business continuity, we have implemented the following:

  • All Synteract staff began working from home last week, with no onsite or face-to-face meetings allowed and abiding by all mandated travel restrictions.
  • I've been in close touch with the country leaders for those areas with more heavily mandated control measures in place, and we will provide whatever support for them and their teams as necessary. For other countries who have not moved to those restrictions yet, we anticipate this to happen and this same Synteract support will apply to them as well.
  • A significant percentage of our team is our Clinical Monitoring workforce, whose daily role is to travel to and to interact with investigative sites. We will now conduct site visits remotely, within our own processes and the given regulatory guidelines.
  • The Executive team has been meeting daily to ensure our internal COVID-19 communications updates are concise and shared in a timely and transparent manner.

We know patients are waiting, and we continue to be guided by this mission. I'm grateful for your partnership, patience, diligence, and support as we collectively navigate this unfolding landscape. Together, we will work through this trying time as a partner and resource, as we stay strong for our patients and continue to help you bring your clinical trials to life.

Be safe and stay strong.
Steve.

Steve Powell
Chief Executive Officer
Synteract

Additional resources:
Centers for Disease Control and Prevention (CDC)
World Health Organization (WHO)
EMA Guidance for Clinical Trials
FDA Guidance for Clinical Trials
European Centre for Disease Prevention and Control

x

Submit RFI / RFP

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

Required

x

Contact Synteract

Tell us how to stay in touch with you:

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

Required

x

 

x

Download Resource

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

*Required

x

To complete your download, please choose an option in the Internet Explorer pop-up window at the bottom of this browser.

x

Download Resource

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

*Required

x

To complete your download, please choose an option in the Internet Explorer pop-up window at the bottom of this browser.

x

Opt In

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

*Required